You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖(02696.HK)就靶向人類BRAF蛋白V600E突變小分子抑制劑RX208與潤新生物訂立許可協議
格隆匯 05-11 17:03

格隆匯5月11日丨復宏漢霖(02696.HK)公佈,於2021年5月11日,公司就靶向人類BRAF蛋白V600E突變的小分子抑制劑RX208與潤新生物訂立藥品技術許可協議。潤新生物將基於必要或合理有用的相關許可專利及許可專有技術,授予公司一項可再許可的獨家許可,供公司在許可區域內研究、開發、生產及商業化許可產品。同時,公司有權將許可產品用於任何人類適應症及任何治療方法(包括但不限於單藥、組合用藥或雞尾酒療法)。許可區域為中國(含港澳台地區)。

公司應向潤新生物支付:首付款合計人民幣9,750萬元,基於許可協議的簽訂、潤新生物發票出具、許可產品的技術文件和資料轉讓進度;監管及商業銷售里程碑付款合計不超過人民幣10.775億元,基於許可產品的各項開發及商業銷售里程碑;及除根據協議條款做出的調整及╱或抵扣外,以年度淨銷售額的8%到12%計的特許權使用費,具體取決於許可區域內許可產品的年度淨銷售額水平。

據悉,許可產品是靶向人類BRAF蛋白V600E突變的小分子抑制劑,在臨牀前研究中展現出優異的療效與安全性,目前處於1期臨牀開發階段。BRAF蛋白是MAPK/ERK信號通路中重要的上游調節因子,其V600E突變可使BRAF蛋白持續激活,是包括結直腸癌、甲狀腺瘤、黑色素瘤在內的多種腫瘤及脂質肉芽腫(ECD)等罕見病的潛在靶點。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account